Sunar Veli, Ateş Öztürk, Korcali Aslan Alma, Karakaş Yusuf, Altundağ Mustafa Kadri
Department of Medical Oncology, Hacettepe University Medical Faculty, Ankara, Turkey.
Department of Medical Oncology, Abdurrahman Yurtaslan Training and Research Hospital, Ankara, Turkey.
Arch Rheumatol. 2018 Aug 16;34(2):141-147. doi: 10.5606/ArchRheumatol.2019.6803. eCollection 2019 Jun.
This study aims to investigate the prevalence of systemic rheumatic diseases (SRDs) among patients with breast cancer (BC) and to identify the clinicopathological characteristics of these patients.
A total of 3,744 female patients with BC (mean age 49±11.7 years; range, 18 to 92 years) followed in Hacettepe University Faculty of Medicine, Medical Oncology Department between January 2006 and December 2015 were retrospectively assessed. Patients with or without SRD were compared in terms of clinicopathological features including age, menopausal state, smoking status, Body Mass Index (BMI), age of menarche, age at first labor, and number of children. The groups were also evaluated regarding tumor grade, stage, estrogen receptor and progesterone receptor expression, human epidermal growth factor receptor 2 overexpression, and survival.
Of the patients analyzed, 68 (1.81%) had concomitant SRD. Among these patients, 33 (48.6%) had rheumatoid arthritis, eight (11.8%) had familial Mediterranean fever, eight (11.8%) had Behçet's disease, four (5.8%) had Sjögren's syndrome, four (5.8%) had systemic lupus erythematosus, six (8.8%) had ankylosing spondylitis, three (4.4%) had systemic sclerosis, one (1.4%) had polymyositis, and one (1.4%) had temporal arteritis. The groups with or without SRDs were similar in terms of age, smoking status, BMI, menopausal state, breast feeding duration, age at menarche and first birth. Stage 1 and 2 BC was more prevalent in SRD patients (74.6% vs. 64.5%, p=0.018). The rate to receive chemotherapy was significantly lower in patients with SRD. However, there was no significant difference in five-year overall survival rates between patients with or without SRD.
Among patients with BC, 1.81% had concomitant SRD. These patients were diagnosed at early stages and given chemotherapy less frequently. However, they had similar survival rates compared to those without SRDs.
本研究旨在调查乳腺癌（BC）患者中系统性风湿性疾病（SRD）的患病率，并确定这些患者的临床病理特征。
回顾性评估2006年1月至2015年12月在哈杰泰佩大学医学院肿瘤内科随访的3744例女性BC患者（平均年龄49±11.7岁；范围18至92岁）。比较有无SRD患者的临床病理特征，包括年龄、绝经状态、吸烟状况、体重指数（BMI）、初潮年龄、首次生育年龄和子女数。还评估了两组患者的肿瘤分级、分期、雌激素受体和孕激素受体表达、人表皮生长因子受体2过表达情况以及生存率。
在分析的患者中，68例（1.81%）患有合并SRD。其中，33例（48.6%）患有类风湿关节炎，8例（11.8%）患有家族性地中海热，8例（11.8%）患有白塞病，4例（5.8%）患有干燥综合征，4例（5.8%）患有系统性红斑狼疮，6例（8.8%）患有强直性脊柱炎，3例（4.4%）患有系统性硬化症，1例（1.4%）患有多发性肌炎，1例（1.4%）患有颞动脉炎。有无SRD的两组患者在年龄、吸烟状况、BMI、绝经状态、母乳喂养时间、初潮年龄和首次生育年龄方面相似。SRD患者中1期和2期BC更为常见（74.6%对64.5%，p=0.018）。SRD患者接受化疗的比例显著较低。然而，有无SRD患者的五年总生存率没有显著差异。
在BC患者中，1.81%患有合并SRD。这些患者在早期被诊断，接受化疗的频率较低。然而，与无SRD的患者相比，他们的生存率相似。
